Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $576.00 million which beat the analyst consensus estimate of $556.79 million by 3.45 percent. This is a 0.70 percent increase over sales of $572.00 million the same period last year.
Calliditas Therapeutics Q4 EPS $(0.01) Beats $(0.57) Estimate, Sales $40.32M Beat $18.93M Estimate
Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.57) by 97.72 percent. This is a 97.23 percent increase over losses of $(0.47) per
